Please assess the completion status of the following clinical trial:

Trial Title: Trial of Miltefosine in Cutaneous Leishmaniasis (Brazil)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed (untreated) cutaneous leishmaniasis with localized lesions and visualization of amastigotes in tissue samples or a positive culture or diagnosed by polymerase chain reaction (PCR) methods or by intradermal skin testing (Montenegro test).~* Number of lesions: 1 to 5 ulcerative lesions.~* Lesion´s diameter: 1 to 5 cm.~* Disease duration: up to three months.~Exclusion Criteria:~Safety concerns:~* Thrombocyte count \<30 x 109/l~* Leukocyte count \<1 x 109/l~* Hemoglobin \<5 g/100 ml~* ASAT, ALAT, AP \>3 times upper limit of normal range~* Bilirubin \>2 times upper limit of normal range~* Serum creatinine or BUN \>1.5 times upper limit of normal range~* Evidence of serious underlying disease (cardiac, renal, hepatic or pulmonary)~* Immunodeficiency or antibody to HIV~* Any non-compensated or uncontrolled condition, such as active tuberculosis, malignant disease, severe malaria, HIV, or other major infectious diseases~* Lactation, pregnancy (to be determined by adequate test) or inadequate contraception in females of childbearing potential for treatment period plus 2 months~Lack of suitability for the trial:~* Negative parasitology (aspirate/smear)or negative Montenegro test~* Any history of prior anti-leishmania therapy~* Any condition which compromises ability to comply with the study procedures~* Concomitant serious infection other than cutaneous~Administrative reasons:~* Lack of ability or willingness to give informed consent (patient and/or parent / legal representative)~* Anticipated non-availability for study visits/procedures

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1.1 (Type: EXPERIMENTAL): Cutaneous leishmaniasis patients in Manaus-Amazonas randomized to receive Miltefosine.
- 1.2 (Type: ACTIVE_COMPARATOR): Cutaneous leishmaniasis patients in Manaus-Amazonas randomized to receive Meglumine antimoniate (standard treatment).
- 2.1 (Type: EXPERIMENTAL): Cutaneous leishmaniasis patients in Corte de Pedra-Bahia randomized to receive Miltefosine.
- 2.2 (Type: ACTIVE_COMPARATOR): Cutaneous leishmaniasis patients in Corte de Pedra-Bahia randomized to receive Meglumine antimoniate (standard treatment).

Based on this trial design, predict the completion outcome and termination type (if applicable).